Meta-analysis of statin and outcomes of coronavirus disease 2019 (COVID-19): Reconsideration is needed.
作者信息
Tandaju Jeremy R, Ii Wang, Barati-Boldaji Reza, Raeisi-Dehkordi Hamidreza
机构信息
Faculty of Medicine Universitas Indonesia Dr. Cipto Mangunkusumo National General Central Hospital, Jakarta, Indonesia.
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
出版信息
Nutr Metab Cardiovasc Dis. 2021 Aug 26;31(9):2737-2739. doi: 10.1016/j.numecd.2021.06.009. Epub 2021 Jul 5.
Abstract
摘要
相似文献
1
Meta-analysis of statin and outcomes of coronavirus disease 2019 (COVID-19): Reconsideration is needed.他汀类药物与2019冠状病毒病（COVID-19）结局的荟萃分析：需要重新考虑。
Nutr Metab Cardiovasc Dis. 2021 Aug 26;31(9):2737-2739. doi: 10.1016/j.numecd.2021.06.009. Epub 2021 Jul 5.
2
Authors' response: Meta-analysis of statin and outcomes of coronavirus disease 2019 (COVID-19).作者回应：他汀类药物与2019冠状病毒病（COVID-19）结局的荟萃分析。
Nutr Metab Cardiovasc Dis. 2021 Aug 26;31(9):2740-2742. doi: 10.1016/j.numecd.2021.06.008. Epub 2021 Jun 29.
3
Statin therapy in COVID-19 infection.新冠病毒感染中的他汀类药物治疗。
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):258-259. doi: 10.1093/ehjcvp/pvaa042.
4
Statin Treatment of COVID-19.他汀类药物治疗新型冠状病毒肺炎
Am J Cardiol. 2020 Dec 1;136:171-173. doi: 10.1016/j.amjcard.2020.09.050. Epub 2020 Sep 28.
5
Statin therapy in COVID-19 infection: much more than a single pathway.新冠病毒感染中的他汀类药物治疗：远不止单一途径。
Eur Heart J Cardiovasc Pharmacother. 2020 Nov 1;6(6):410-411. doi: 10.1093/ehjcvp/pvaa055.
6
Letter in response to the article: Pros and cons for use of statins in 59 people with coronavirus disease-19 (COVID-19)(Ray, S et al.).致编辑的信：关于“59例冠状病毒病（COVID-19）患者使用他汀类药物的利弊”一文的回应（雷，S等人）
Diabetes Metab Syndr. 2021 Jan-Feb;15(1):21. doi: 10.1016/j.dsx.2020.11.017. Epub 2020 Nov 25.
7
Meta-analysis of Effect of Statins in Patients with COVID-19.他汀类药物对新型冠状病毒肺炎患者影响的荟萃分析
Am J Cardiol. 2020 Nov 1;134:153-155. doi: 10.1016/j.amjcard.2020.08.004. Epub 2020 Aug 12.
8
Statin therapy is associated with less ICU admissions in COVID-19 patients.他汀类药物治疗与新冠病毒感染患者入住重症监护病房的人数减少有关。
Minerva Anestesiol. 2021 Aug;87(8):951-952. doi: 10.23736/S0375-9393.21.15600-7. Epub 2021 Mar 10.
9
Should statins be considered for the management of mucormycosis in COVID-19?在新冠病毒感染（COVID-19）中，是否应考虑使用他汀类药物来治疗毛霉菌病？
Diabetes Metab Syndr. 2021 Jul-Aug;15(4):102162. doi: 10.1016/j.dsx.2021.05.035. Epub 2021 Jun 5.
10
Use of statins in patients with COVID-19.他汀类药物在新冠肺炎患者中的应用。
QJM. 2020 Aug 1;113(8):604-605. doi: 10.1093/qjmed/hcaa172.
引用本文的文献
1
Survival impact of previous statin therapy in patients hospitalized with COVID-19.既往他汀类药物治疗对COVID-19住院患者生存的影响。
Med Clin (Engl Ed). 2023 Jan 5;160(1):1-9. doi: 10.1016/j.medcle.2022.03.021. Epub 2022 Dec 7.
2
Survival impact of previous statin therapy in patients hospitalized with COVID-19.COVID-19 住院患者既往他汀类药物治疗对生存的影响。
Med Clin (Barc). 2023 Jan 5;160(1):1-9. doi: 10.1016/j.medcli.2022.03.015. Epub 2022 May 8.
3
Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂的使用与降低 COVID-19 美国退伍军人的死亡率和其他疾病结局相关。
Drugs. 2022 Jan;82(1):43-54. doi: 10.1007/s40265-021-01639-2. Epub 2021 Dec 16.
4
COVID-19 and lipids. The role of lipid disorders and statin use in the prognosis of patients with SARS-CoV-2 infection.COVID-19 和脂质。脂质紊乱和他汀类药物使用在 SARS-CoV-2 感染患者预后中的作用。
Lipids Health Dis. 2021 Oct 25;20(1):141. doi: 10.1186/s12944-021-01563-0.
Zotero 插件